GSK Pursuing Late-Stage Inflammatory Bowel Disease Treatment With ChemoCentryx
Collaboration includes potential payments of up to $1.5 bil. for co-development rights to Traficet-EN and other chemokine and chemoattractant receptors.
Collaboration includes potential payments of up to $1.5 bil. for co-development rights to Traficet-EN and other chemokine and chemoattractant receptors.